Background and Objectives: The emergence of ESBL-producing Escherichia coli in the community is a major public health concern, as these strains can act as reservoirs for resistance genes and cause various infections. Additionally, plasmid-mediated AmpC beta-lactamases have further complicated treatment options by conferring resistance to broad-spectrum beta-lactam antibiotics. This study aims to assess the carriage rate of ESBL- and AmpC-producing E. coli among patients attending a tertiary care hospital in a rural Faridabad district.Materials and Methods: This prospective cross-sectional study was conducted at Al-Falah School of Medical Sciences and Research Centre, Faridabad, from May to July 2022. 102 Non-pathogenic E.coli isolated from 150 stool samples received in the microbiology laboratory, were included in the study. Antibiotic susceptibility testing was performed, as per the CLSI 2022 guidelines. All isolates were screened for the production of ESBL and AmpC using ceftazidime and cefotaxime for ESBL and cefoxitin for AmpC. ESBL production was confirmed using the double disk diffusion test and AmpC production was confirmed using the boronic acid and cloxacillin combination double disk test.Results: Of the 150 stool samples, 102 non-pathogenic E.coli isolates were grown. out of 102 isolates, 52.94% were ESBL producers, while 28.43% were AmpC producers. Additionally, 18.63% of the isolates produced both ESBL and AmpC, indicating a substantial burden of antimicrobial resistance. Most of these isolates were multi-drug-resistant bacteria. The least resistance was seen against carbapenems. Conclusion: The alarming fecal carriage rate of multi-drug resistant ESBL-producing E. coli in a rural community highlights the risk for resistance transmission between non-pathogenic and pathogenic bacteria.